Kardium announces US$ 104 million in new financing for innovative Atrial Fibrillation Treatment
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Launches collaborative centre for translational research in head and neck cancer
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Subscribe To Our Newsletter & Stay Updated